Stephen Chan
0000-0001-8998-5480
Chinese University of Hong Kong
232 papers found
Refreshing results…
Abstract 1241: A preclinical study of the combined treatment of arginase and canavanine in pancreatic cancer
A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma
A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC).
Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
Epidemiology of lung cancer: A joinpoint analysis of temporal incidence and mortality trends in 38 countries.
Validating the ALBI grade: Its current and future use in HCC prognostication
Liver stiffness measurement predicts high‐grade post‐hepatectomy liver failure: A prospective cohort study
KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.
KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion
Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance
Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data
Phase I/II study of FGF401 in adult patients (pts) with hepatocellular carcinoma (HCC) or solid tumors and positive FGFR4/KLB expression
Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study
Incorporating albumin–bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma
Comments on “Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients”
What do oncologists need to know about biosimilar products?
Applicability of albumin‐bilirubin‐based Japan integrated staging score in hepatitis B‐associated hepatocellular carcinoma
Missing publications? Search for publications with a matching author name.